- Date2024-09-06
Publication of Review Result of the Twelfth Pharmaceutical Reimbursement Evaluation Committee of 2022
□ The Health Insurance Review and Assessment Service (President Kim Sun-min) releases the results of the deliberations of the 12th Pharmaceutical Reimbursement Evaluation Committee in 2022 as follows.
○ Result of the review of the adequacy of the healthcare benefit for the pharmaceutical applied for assessment
|
Product |
Pharmaceutical company |
Efficacy and effectiveness |
Deliberation results |
|
Erlyda Tablet (Apalutamide) |
Janssen Korea, Inc |
Hormone- responsive Metastaticprostatecancer |
Reimbursement is adequate if the terms of the Pharmaceutical Reimbursement Evaluation Committee's proposal are accepted. |
|
Reba Eye Drops 2% etc 2product (Rebamipide) |
Kukjepharm co., Ltd, Samil-pharm co., Ltd |
Keratoconjunctival Epithelial Disorders in Adult Dry Eye Patients |
Reimbursement is adequate. |
※ Pursuant to Article 11(2) of the Rules on the Criteria for National Health Insurance Reimbursement, the President of the Health Insurance Review and Assessment Service evaluates the adequacy of reimbursement for drugs after deliberation by the Pharmaceutical Reimbursement Evaluation Committee. The final evaluation results may be subject to change if there are changes in the detailed reimbursement scope and items of the drug, changes in the approval of the item applied for decision, or revocation (cancellation) of the approval.
